Sudden Infant Death: Clinical Trials

10 trials for Sudden Infant Death, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 2 terminated, 1 active not recruiting, 1 recruiting. 10 Phase 1, 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 110Completed 5, Terminated 2, Active not recruiting 1, Recruiting 1, Withdrawn 1
Phase 27Completed 4, Terminated 2, Active not recruiting 1

Follow Sudden Infant Death: new trials by email Literature Review of Sudden Infant Death trials Research Report on Sudden Infant Death

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS II
Genetic HMI-203 - Mucopolysaccharidosis II
Phase 1WithdrawnHomology Medicines, Inc2022-09-082023-08-28
PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)
Aldurazyme (laronidase) - MPS I, MPS II
Phase 1RecruitingUniversity of California, San Francisco102021-07-012026-03-17
RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome)
RGX-121 - Mucopolysaccharidosis Type II (MPS II)
Phase 1 / Phase 2CompletedREGENXBIO Inc.62021-03-112025-01-28
A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome
tividenofusp alfa - Mucopolysaccharidosis II
Phase 1 / Phase 2Active not recruitingDenali Therapeutics Inc.472020-07-162025-08-07
Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II
SB-913 - Mucopolysaccharidosis II, MPS II
Phase 1 / Phase 2TerminatedSangamo Therapeutics92017-05-112022-10-25
Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome
AGT-182 - Mucopolysaccharidosis II
Phase 1CompletedArmaGen, Inc62015-04-012018-09-18
Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders
hematopoietic stem cell infusion - Hurler Syndrome (MPS I), Hurler-Scheie Syndrome
Phase 1 / Phase 2TerminatedTalaris Therapeutics Inc.32011-04-012023-04-12
An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment
Idursulfase-IT, Elaprase - Hunter Syndrome
Phase 1 / Phase 2CompletedTakeda152010-08-012025-08-06
To Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome Patients
GC1111_0.5mg/kg, GC1111_1.0mg/kg, Elaprase_0.5mg/kg - Mucopolysaccharidosis II
Phase 1 / Phase 2CompletedGreen Cross Corporation312010-05-012012-02-14
A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®
Control, Idursulfase IT (1 mg), Idursulfase IT (10 mg) - Hunter Syndrome
Phase 1 / Phase 2CompletedShire162009-11-182021-06-28

Narrower conditions

Mucopolysaccharidosis II (9)  ·  Lysosomal Storage Diseases (2)  ·  Adrenoleukodystrophy (1)  ·  Gaucher Disease (1)  ·  Leukodystrophy, Globoid Cell (1)  ·  Leukodystrophy, Metachromatic (1)  ·  Mucopolysaccharidoses (1)  ·  Mucopolysaccharidosis I (1)  ·  Mucopolysaccharidosis III (1)  ·  Mucopolysaccharidosis IV (1)  ·  Mucopolysaccharidosis VI (1)  ·  Mucopolysaccharidosis VII (1)  ·  Niemann-Pick Diseases (1)  ·  Sandhoff Disease (1)

Broader conditions

Carbohydrate Metabolism, Inborn Errors (10)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10)  ·  Connective Tissue Diseases (10)  ·  Death (10)  ·  Death, Sudden (10)  ·  Genetic Diseases, Inborn (10)  ·  Infant Death (10)  ·  Metabolic Diseases (10)  ·  Metabolism, Inborn Errors (10)  ·  Mucinoses (10)  ·  Nervous System Diseases (10)  ·  Nutritional and Metabolic Diseases (10)  ·  Pathologic Processes (10)  ·  Pathological Conditions, Signs and Symptoms (10)  ·  Skin and Connective Tissue Diseases (10)

Interventions

idursulfase (2)  ·  GAA protein, human (1)  ·  GALNS protein, human (1)  ·  Iduronidase (1)  ·  Sebelipase alfa (1)  ·  Stem Cell Transplantation (1)  ·  galsulfase (1)  ·  vestronidase alfa (1)

Sponsors

ArmaGen, Inc (1)  ·  Denali Therapeutics Inc. (1)  ·  Green Cross Corporation (1)  ·  Homology Medicines, Inc (1)  ·  REGENXBIO Inc. (1)  ·  Sangamo Therapeutics (1)  ·  Shire (1)  ·  Takeda (1)  ·  Talaris Therapeutics Inc. (1)  ·  University of California, San Francisco (1)

Countries

United States (9)  ·  Canada (4)  ·  United Kingdom (3)  ·  Germany (1)  ·  Netherlands (1)  ·  Philippines (1)  ·  South Korea (1)

Top investigators

Patrice Rioux, MD PhD (1)  ·  Sam Lu, MD (1)  ·  Suzanne T Ildstad, MD (1)  ·  Tippi MacKenzie, MD (1)

Results publications

PMID 15324318, PMID 19948615, PMID 21637107, PMID 23497636, PMID 23510062, PMID 28374935, PMID 28657663, PMID 30337566, PMID 32102934, PMID 35588317, PMID 36299240, PMID 37955580, PMID 39891377, PMID 41467650, PMID 9918480

NIH funding

2019 (1), 2023 (1)